Biohaven Ltd
BHVN
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.65B
Close$
$-0.51
103.4% downside
Current Fair Value
103.4% downsideOvervalued by 103.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.65 Billion |
|---|---|
| Enterprise Value | $1.65 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.86 |
| Beta | 3.14 |
| Outstanding Shares | 147,615,197 |
Return
| Return on Equity | -500.14% |
|---|---|
| Return on Assets | -138.87% |
| Return on Invested Capital | -159.43% |
Valuation & Multiples
| P/E Ratio | -2.74 |
|---|---|
| PEG | 6.67 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.5 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | 2.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-0.86
Average shareholder expectationRevenue Estimate
$267,436
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-0.77
Average shareholder expectationRevenue Estimate
$490,492
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 25.50% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.03%▼ 117.10% |
|---|---|
| Total Invested | $22.54M▼ 98.12% |
| Investors Holding | 11▼ 281.00% |
ESG Score
No data
About Biohaven Pharmaceutical Holding Company Ltd
CEO: Vlad Coric